Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 10, 2011 Brian Orelli	Breathe Easier, Join the Competition Novartis' strategy is a good one.
The Motley Fool June 25, 2010 Brian Orelli	Merck Breathes Life Into an Acquired Pipeline The acquisition is paying off with newly approved drugs.
The Motley Fool January 15, 2010 Brian Orelli	Oops, Sorry About That, Pfizer The FDA says there's no problem with Spiriva after all.
The Motley Fool November 11, 2010 Brian Orelli	ATTRACTing Clinical Trial Failure Let's not make it a habit, Novartis. Novartis is dropping development of lung-cancer treatment ASA404 after a second failed phase 3 trial.
The Motley Fool June 4, 2010 Brian Orelli	This Cancer Drug's on a Roll Novartis' Afinitor scores another win.
Chemistry World September 25, 2013 Phillip Broadwith	New respiratory drugs neck and neck A flurry of regulatory approvals has seen three new drugs approved for asthma and chronic obstructive pulmonary disease in the European and Japanese markets.
The Motley Fool March 30, 2010 Brian Orelli	Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers.
Chemistry World June 10, 2013 Phillip Broadwith	AstraZeneca stocks pipeline with acquisitions AZ is also buying Omthera Pharmaceuticals for an up-front payment of $323 million, with a potential $120 million in milestone payments on offer.
Chemistry World July 31, 2014 Phillip Broadwith	AstraZeneca stocks respiratory and cancer pipelines AstraZeneca has agreed to buy Spanish firm Almirall's respiratory drug assets for $875 million up front, plus up to $1.2 billion in performance milestone payments.
American Family Physician February 1, 2006	Chronic Obstructive Pulmonary Disease: What You Should Know An informative patient guide: What is COPD?... What causes COPD?... How do I know if I have COPD?... What can I do about my COPD?...
The Motley Fool April 14, 2005 Brian Gorman	Novartis Moves on Multiple Fronts Even with its investment in a potential blockbuster, Novartis remains remarkably diversified. Investors can rest assured, though, that the company's strategy won't leave it as vulnerable as other outfits.
The Motley Fool June 3, 2011 Frank Vinluan	GSK Sees Positive Results on Asthma, COPD Drug Expected to Succeed Advair GSK gets good news.
The Motley Fool December 8, 2008 Brian Orelli	A Checkup for Makers of Asthma Drugs Because of recent events, GlaxoSmithKline, AstraZeneca, Novartis, and Schering-Plough all face extra scrutiny from the FDA.
The Motley Fool September 30, 2009 Brian Orelli	Less Is More for Novartis That makes it simple enough.
American Family Physician May 15, 2004	Chronic Obstructive Pulmonary Disease An overview of chronic obstructive pulmonary disease (COPD), a disease that blocks the large and small airways of your lungs.
The Motley Fool May 28, 2010 Brian Orelli	This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope.
American Family Physician February 15, 2006 Dewar & Curry	Chronic Obstructive Pulmonary Disease: Diagnostic Considerations Chronic obstructive pulmonary disease is characterized by the gradual progression of irreversible airflow obstruction and increased inflammation in the airways and lung parenchyma that is generally distinguishable from the inflammation caused by asthma.
The Motley Fool June 11, 2010 Brian Orelli	25 to 0! Now That's a Ringing Endorsement Novartis flies through its advisory panel meeting nearly unscathed.
American Family Physician August 15, 2001	Chronic Obstructive Pulmonary Disease What is chronic obstructive pulmonary disease (also called COPD)?... Who gets COPD?... How can I find out if I have COPD?... How is COPD treated?... I know I have COPD. Now what will happen?...
The Motley Fool March 3, 2011 Brian Orelli	3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year.
The Motley Fool March 16, 2005 Cliff Malings	Nice of You to Notice Novartis The Street finally pays attention to a longtime pharma winner on news of a major generic-drug acquisition.
Nurse Practitioner May 2011 Chris Garvey	Best Practices in Chronic Obstructive Pulmonary Disease Chronic obstructive pulmonary disease is a common, preventable, treatable, and often progressive disorder characterized by airflow limitation that is not fully reversible.
The Motley Fool October 23, 2006 Brian Lawler	No Slowing Novartis The Swiss pharmaceutical company shows strength in nearly all its divisions. Novartis looks like a good investment for risk-adverse investors searching for a large-cap pharma stock.
The Motley Fool July 16, 2009 Brian Orelli	A Strong Dollar Can Hurt Novartis makes it through a hard quarter.
Pharmaceutical Executive December 1, 2008 Ron Feemster	The 2008 Pipeline Report We scrub industry's pipeline to find the drugs that everyone will be talking about in 2009 and beyond.
The Motley Fool January 20, 2005 Stephen D. Simpson	Novartis Posts a Swiss Miss The Swiss drug giant has a strong pipeline, but moderate growth and high valuation suggest little room for error.
The Motley Fool July 7, 2010 Dave Mock	A Big Upgrade for Novartis This bullish call comes from more than just one analyst.
The Motley Fool July 16, 2010 Brian Orelli	A Positive Sign for Pharma Earnings Season Strong first-half results drove Novartis to increase its sales guidance for the year.
The Motley Fool September 24, 2010 Brian Orelli	So Long and Thanks for All the Drug Candidates Alnylam and Novartis end their five-year partnership.
The Motley Fool March 29, 2006 Stephen D. Simpson	Novartis Bulks Up Its Pipeline The Swiss drug giant once again pays up to add trial candidates to its portfolio. Investors, take note.
BusinessWeek June 11, 2009 Kerry Capell	Novartis: Radically Remaking Its Drug Business CEO Dan Vasella's growth mantra for Novartis is follow the science, not the financials.
The Motley Fool October 22, 2007 Brian Lawler	No Catastrophes at Novartis Novartis stays on track with its third-quarter results. Investors, take note.
Nursing April 2011 Smith & Tasota	Smoking Out the Dangers of COPD An overview of the guidelines for preventing, diagnosing, and treating COPD.
The Motley Fool June 6, 2008 Brian Lawler	Nothing Can Stop Novartis! Swiss pharmaceutical giant Novartis has bucketloads of cash, and apparently, it isn't afraid to use them.
The Motley Fool December 30, 2008 Brian Orelli	A Shot in the Arm for Novartis' Pipeline The company picks up the rights to a vaccine that fights a virus.
Pharmaceutical Executive December 1, 2006	Pipeline 32 compounds that are the early fruit of pharma's investment in targeted drug design.
The Motley Fool June 7, 2006 Stephen D. Simpson	Novartis Can't Say No The Swiss drug giant signs more deals to boost its pipeline. Investors, here is a strong company in a weak sector that's still somewhat undervalued -- not exactly the worst story of the week.
The Motley Fool July 27, 2006 Stephen D. Simpson	AstraZeneca Needs a Rest The stock isn't too expensive, but it's no longer a bargain.
The Motley Fool April 7, 2011 Brian Orelli	When Zombies Attack, Investors Win Novartis is hoping that Prexige has as much success coming back from the dead as Tysabri has.
The Motley Fool April 25, 2007 Brian Lawler	Nothing Wrong With Novartis Novartis releases first-quarter financial results. Investors, take note.
The Motley Fool September 22, 2010 Jordan DiPietro	A Huge Victory for Novartis MS oral drug is approved.
American Journal of Nursing March 2012 Corbridge et al.	An Evidence-Based Approach to COPD: Part 1 This article, the first in a two-part series on COPD, outlines current guidelines and other evidence-based recommendations on diagnosing and managing stable COPD in the outpatient setting.
American Family Physician April 15, 2005 Karnani, Reisfield & Wilson	Evaluation of Chronic Dyspnea Chronic dyspnea is defined as dyspnea lasting more than one month. Information is presented on diagnosis, assessment and treatment for chronic dyspnea.
Pharmaceutical Executive October 1, 2005	Successful Alliances: Novartis and Idenix Share the Secrets of Success Novartis Pharma AG CEO Thomas Ebeling and Idenix founder, CEO, and chairman Jean-Pierre Sommadossi discuss the mutual benefits and challenges of maintaining a successful partnership.
The Motley Fool July 17, 2007 Brian Lawler	Still Strong at Novartis For investors who are willing to filter the negative news and are patient enough to wait for recently launched branded compounds to help its top-line growth, Novartis is worth a look
The Motley Fool January 22, 2007 Brian Lawler	Another Busy Year in Store for Novartis Trying to place a value on Novartis is a tough thing to do now with so many important drugs awaiting regulatory review and its addiction to acquisitions and divestitures making financial comparisons between the years tough.
The Motley Fool August 17, 2009 Brian Orelli	Preparing for a Home Run Some good news and bad news for companies selling drugs to treat multiple sclerosis, after Novartis announces Extavia has been approved by the FDA.
The Motley Fool September 20, 2005 Brian Gorman	Novartis Stays Focused New developments at the drug giant suggest the company is on track. Investors, take note.
Nursing November 2011 Lawson & Pruitt	Issues in Obesity, Part 2: Obesity Weighs Heavily on Lung Function A look at the impact of obesity on asthma, chronic obstructive pulmonary disease (COPD), and sleep apnea.
The Motley Fool July 14, 2005 Stephen D. Simpson	These Swiss Don't Miss Aside from a hiccup in margins, Novartis' drug business continues to shine. This pharma is a solid middle-of-the-road play with reasonable valuation, a solid pipeline, and a not-so-secret weapon in its Sandoz generics business.